Curran Terrie 4

What Happened

• Terrie Curran, a non-employee director of Arcutis Biotherapeutics (ARQT), was granted compensation-related equity on June 5, 2026: 5,778 restricted stock units (RSUs) and 16,667 derivative awards (total 22,445 units). All awards were recorded at $0.00 (no cash paid). These are grants — not open-market purchases or sales.

Key Details

• Transaction date: June 5, 2026. Report filed June 9, 2026 (timely under the two-business-day Form 4 rule).
• Prices: $0.00 per unit (award/grant).
• Total units granted: 5,778 RSUs + 16,667 derivative awards = 22,445 units.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1: The 5,778 RSUs are payable 1-for-1 upon vesting; the Reporting Person elected to defer settlement under an RSU Deferral Election Form (adopted Dec 22, 2025).
  • F2: The 16,667 derivative awards’ underlying shares vest/become exercisable 100% on the earlier of the first anniversary of the grant date or immediately before the next annual meeting, subject to continued service.
• Filing timeliness: filed June 9, 2026 for a June 5 transaction — appears timely.

Context

• These awards are routine director compensation (RSUs/derivative awards) that convert to common stock only upon vesting; no shares were sold or purchased on the open market. Such grants are common for non-employee directors and reflect compensation rather than an immediate trading signal.